

## CLAIMS

What is claimed is:

1. A human or humanized antibody that binds to human CD94, wherein:  
  
    (a) binding of the antibody to human CD94 does not block binding between human CD94 and human HLA-E; and/or  
  
    (b) the antibody binds to human CD94 and cynomolgus CD94.
2. The antibody of claim 1, wherein the antibody binds human CD94 expressed on the surface of a cell, optionally a human natural killer (NK) cell or a CD8+ CD94+ T cell.
- ~~3. The antibody of claim 2, wherein the cell is a human natural killer (NK) cell.~~
- ~~4. A human or humanized antibody that binds to human CD94 and cynomolgus CD94.~~
- ~~5. The antibody of claim 4, wherein the antibody binds human CD94 expressed on the surface of a cell.~~
- ~~6. The antibody of claim 5, wherein the cell is a human natural killer (NK) cell.~~
- ~~7. The antibody of any one of claims 4-6, wherein binding of the antibody to human CD94 does not block binding between human CD94 and human HLA-E.~~
- ~~8. The antibody of any one of claims 1-3 and 7, wherein binding of the antibody to cells expressing human CD94 blocks less than 20% of HLA-E binding to the human CD94.~~
- ~~9. The antibody of any one of claims 1-8, wherein incubating the antibody with a cell expressing human CD94 on its surface for 24 hours at 37°C results in a decrease in surface antibody staining of less than 50% due to internalization.~~
- ~~10. The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:6.~~

11.3. The antibody of claim 1 or claim 2~~any one of claims 1-9~~, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, and wherein:

(a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64;

(b) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:6;

(c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12;

(d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18;

(e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(g) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:46;

(h) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52;

(i) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61;

(j) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:111; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64;

(k) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:88, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(l) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:94; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(m) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:95, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:96, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:97; and wherein the VL domain comprises a CDR-L1 comprising the amino

acid sequence of SEQ ID NO:98, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:100;

(n) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:114; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52;

(o) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:101, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:102, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:103; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:104, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61;

(p) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(q) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61;

(r) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:93; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;

(s) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56;

(t) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:116, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:117, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:118; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:56;

(u) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:106, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:107; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61; or

(v) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:94; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35.

12.4. The antibody of claim 340 or claim 11, wherein:

(a) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:81, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:82, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:81, and the VL domain comprises the amino acid sequence of SEQ ID NO:82;

(b) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:20, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:19, and the VL domain comprises the amino acid sequence of SEQ ID NO:20;

(c) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:22, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:21, and the VL domain comprises the amino acid sequence of SEQ ID NO:22;

(d) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at

least 80% sequence identity to the amino acid sequence of SEQ ID NO:24, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:23, and the VL domain comprises the amino acid sequence of SEQ ID NO:24;

(e) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:65, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:66, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:65, and the VL domain comprises the amino acid sequence of SEQ ID NO:66;

(f) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:69, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:70, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:69, and the VL domain comprises the amino acid sequence of SEQ ID NO:70;

(g) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:71, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:72, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:71, and the VL domain comprises the amino acid sequence of SEQ ID NO:72;

(h) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:73, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:74, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:73, and the VL domain comprises the amino acid sequence of SEQ ID NO:74;

(i) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:77, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:78, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:77, and the VL domain comprises the amino acid sequence of SEQ ID NO:78;

(j) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:67, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:68, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:67, and the VL domain comprises the amino acid sequence of SEQ ID NO:68;

(k) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:75, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:76, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:75, and the VL domain comprises the amino acid sequence of SEQ ID NO:76; or

(l) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:79, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:80, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO:79, and the VL domain comprises the amino acid sequence of SEQ ID NO:80.

~~13. —The antibody of claim 12, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:19, and the VL domain comprises the amino acid sequence of SEQ ID NO:20.~~

~~14. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:12.~~

~~15. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:12.~~

~~16. —The antibody of claim 14 or claim 15, wherein the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:22.~~

17. —The antibody of claim 16, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:21, and the VL domain comprises the amino acid sequence of SEQ ID NO:22.

18. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:18.

19. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:18.

20. —The antibody of claim 18 or claim 19, wherein the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:24.

21. —The antibody of claim 20, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:23, and the VL domain comprises the amino acid sequence of SEQ ID NO:24.

22. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises a CDR-H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:30, a CDR-H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:31, and a CDR-H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR-L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR-L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid



sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; or

(f) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:47, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:48, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:63, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:64.

23. — The antibody of any one of claims 4-6, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:36, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:37, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35;

(b) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:53, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:54, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:50, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:45, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:56; or

(c) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:83, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:84, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:86, a

CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61.

24. — The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

- (a) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;
  - (b) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR H2 comprising the amino acid sequence of SEQ ID NO:39, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;
  - (c) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:41, a CDR H2 comprising the amino acid sequence of SEQ ID NO:42, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:43; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:44, a CDR L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:46;
  - (d) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:49; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR L2 comprising the amino acid sequence of SEQ ID NO:51, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:52;
  - (e) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:57, a CDR H2 comprising the amino acid sequence of SEQ ID NO:58, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:59; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:60, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:61;
- or
- (f) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:47, a CDR H2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:64.

25. —The antibody of any one of claims 1-9, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

- (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:88, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;
  - (b) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:94; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:35;
  - (c) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:95, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:96, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:97; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:98, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:100;
  - (d) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:114; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:52;
  - (e) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:101, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:102, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:103; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:104, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:61;
- or

- (f) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:111; and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:64.

26. —The antibody of any one of claims 4-6, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

- (a) the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR-H3 comprising the

amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;  
(b) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:53, a CDR H2 comprising the amino acid sequence of SEQ ID NO:54, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:55; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:50, a CDR L2 comprising the amino acid sequence of SEQ ID NO:45, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:56;  
or

(c) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:83, a CDR H2 comprising the amino acid sequence of SEQ ID NO:84, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:86, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:61.

27. — The antibody of any one of claims 4-6, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:93; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;  
(b) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:116, a CDR H2 comprising the amino acid sequence of SEQ ID NO:117, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:118; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:56;  
or

(c) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR H2 comprising the amino acid sequence of SEQ ID NO:106, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:107; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:61.

28. — The antibody of any one of claims 1-9, 22, 24, and 25, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:65, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:66;

- (b) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:69, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:70;
- (c) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:71, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:72;
- (d) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:73, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:74;
- (e) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:77, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:78; or
- (f) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:81, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:82.

29. — The antibody of claim 28, wherein:

- (a) the VH domain comprises the amino acid sequence of SEQ ID NO:65, and the VL domain comprises the amino acid sequence of SEQ ID NO:66;
- (b) the VH domain comprises the amino acid sequence of SEQ ID NO:69, and the VL domain comprises the amino acid sequence of SEQ ID NO:70;
- (c) the VH domain comprises the amino acid sequence of SEQ ID NO:71, and the VL domain comprises the amino acid sequence of SEQ ID NO:72;
- (d) the VH domain comprises the amino acid sequence of SEQ ID NO:73, and the VL domain comprises the amino acid sequence of SEQ ID NO:74;
- (e) the VH domain comprises the amino acid sequence of SEQ ID NO:77, and the VL domain comprises the amino acid sequence of SEQ ID NO:78; or
- (f) the VH domain comprises the amino acid sequence of SEQ ID NO:81, and the VL domain comprises the amino acid sequence of SEQ ID NO:82.

30. — The antibody of any one of claims 4-6, 23, 26, and 27, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

- (a) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:67, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:68;
- (b) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:75, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:76; or

~~(c) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:79, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:80.~~

31. — ~~The antibody of claim 30, wherein:~~

- ~~(a) the VH domain comprises the amino acid sequence of SEQ ID NO:67, and the VL domain comprises the amino acid sequence of SEQ ID NO:68;~~
- ~~(b) the VH domain comprises the amino acid sequence of SEQ ID NO:75, and the VL domain comprises the amino acid sequence of SEQ ID NO:76; or~~
- ~~(c) the VH domain comprises the amino acid sequence of SEQ ID NO:79, and the VL domain comprises the amino acid sequence of SEQ ID NO:80.~~

32. — ~~An antibody that binds to human CD94, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:4, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:5, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:6.~~

33. — ~~The antibody of claim 30, wherein the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:1, a CDR H2 comprising the amino acid sequence of SEQ ID NO:2, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:3; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:4, a CDR L2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:6.~~

34. — ~~The antibody of claim 30 or claim 31, wherein the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:19, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:20.~~

35. — ~~The antibody of claim 32, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:19, and the VL domain comprises the amino acid sequence of SEQ ID NO:20.~~

36. — ~~An antibody that binds to human CD94, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of~~

SEQ ID NO:7, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:8, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:10, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:11, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:12.

37. —The antibody of claim 34, wherein the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:7, a CDR H2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:9; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:10, a CDR L2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:12.

38. —The antibody of claim 34 or claim 35, wherein the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:21, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:22.

39. —The antibody of claim 36, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:21, and the VL domain comprises the amino acid sequence of SEQ ID NO:22.

40. —An antibody that binds to human CD94, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:13, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:14, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:16, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:17, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:18.

41. —The antibody of claim 38, wherein the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:13, a CDR H2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:15; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:16, a CDR L2 comprising the amino acid sequence of SEQ ID NO:17, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:18.

42. —The antibody of claim 38 or claim 39, wherein the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:23, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:24.

43. —The antibody of claim 40, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:23, and the VL domain comprises the amino acid sequence of SEQ ID NO:24.

44. —An antibody that binds to human CD94, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:30, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:31, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35;

(b) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:36, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:37, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:38; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35;

(c) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:36, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:39, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:40; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35;



(h) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:83, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:84, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:85; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:86, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; or

(i) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:47, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:48, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:62; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:63, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:64.

45. —An antibody that binds to human CD94, wherein the antibody comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein:

(a) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:88, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:35;

(b) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:92, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:93; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid



sequence of SEQ ID NO:99, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:56;

(g) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:101, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:102, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:103; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:104, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61;

(h) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:105, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:106, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:107; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:108, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:61; or

(i) the VH domain comprises a CDR H1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:109, a CDR H2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:110, and a CDR H3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:111; and wherein the VL domain comprises a CDR L1 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:112, a CDR L2 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:113, and a CDR L3 comprising an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:64.

46. — The antibody of claim 44, wherein:

(a) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:30, a CDR H2 comprising the amino acid sequence of SEQ ID NO:31, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:32; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:33, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;

(b) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR H2 comprising the amino acid sequence of SEQ ID NO:37, and a CDR H3 comprising the



comprising the amino acid sequence of SEQ ID NO:63, a CDR L2 comprising the amino acid sequence of SEQ ID NO:34, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:64.

47. — The antibody of claim 45, wherein:

- (a) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising the amino acid sequence of SEQ ID NO:88, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:89; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;
- (b) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:93; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;
- (c) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:87, a CDR H2 comprising the amino acid sequence of SEQ ID NO:92, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:94; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:90, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:35;
- (d) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:95, a CDR H2 comprising the amino acid sequence of SEQ ID NO:96, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:97; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:98, a CDR L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:100;
- (e) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:114; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:52;
- (f) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:116, a CDR H2 comprising the amino acid sequence of SEQ ID NO:117, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:118; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:115, a CDR L2 comprising the amino acid sequence of SEQ ID NO:99, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:56;
- (g) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:101, a CDR H2 comprising the amino acid sequence of SEQ ID NO:102, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:103; and wherein the VL domain comprises a CDR L1

~~comprising the amino acid sequence of SEQ ID NO:104, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:61;~~  
~~(h) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR H2 comprising the amino acid sequence of SEQ ID NO:106, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:107; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR L2 comprising the amino acid sequence of SEQ ID NO:91, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:61;~~  
~~or~~

~~(i) the VH domain comprises a CDR H1 comprising the amino acid sequence of SEQ ID NO:109, a CDR H2 comprising the amino acid sequence of SEQ ID NO:110, and a CDR H3 comprising the amino acid sequence of SEQ ID NO:111; and wherein the VL domain comprises a CDR L1 comprising the amino acid sequence of SEQ ID NO:112, a CDR L2 comprising the amino acid sequence of SEQ ID NO:113, and a CDR L3 comprising the amino acid sequence of SEQ ID NO:64.~~

48. — The antibody of any one of claims 44-47, wherein:

~~(a) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:65, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:66;~~

~~(b) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:67, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:68;~~

~~(c) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:69, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:70;~~

~~(d) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:71, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:72;~~

~~(e) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:73, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:74;~~

~~(f) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:75, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:76;~~

~~(g) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:77, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:78;~~

(h) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:79, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:80; or  
(i) the VH domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:81, and the VL domain comprises an amino acid sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO:82.

49. — The antibody of claim 48, wherein:

(a) the VH domain comprises the amino acid sequence of SEQ ID NO:65, and the VL domain comprises the amino acid sequence of SEQ ID NO:66;  
(b) the VH domain comprises the amino acid sequence of SEQ ID NO:67, and the VL domain comprises the amino acid sequence of SEQ ID NO:68;  
(c) the VH domain comprises the amino acid sequence of SEQ ID NO:69, and the VL domain comprises the amino acid sequence of SEQ ID NO:70;  
(d) the VH domain comprises the amino acid sequence of SEQ ID NO:71, and the VL domain comprises the amino acid sequence of SEQ ID NO:72;  
(e) the VH domain comprises the amino acid sequence of SEQ ID NO:73, and the VL domain comprises the amino acid sequence of SEQ ID NO:74;  
(f) the VH domain comprises the amino acid sequence of SEQ ID NO:75, and the VL domain comprises the amino acid sequence of SEQ ID NO:76;  
(g) the VH domain comprises the amino acid sequence of SEQ ID NO:77, and the VL domain comprises the amino acid sequence of SEQ ID NO:78;  
(h) the VH domain comprises the amino acid sequence of SEQ ID NO:79, and the VL domain comprises the amino acid sequence of SEQ ID NO:80; or  
(i) the VH domain comprises the amino acid sequence of SEQ ID NO:81, and the VL domain comprises the amino acid sequence of SEQ ID NO:82.

50. — The antibody of any one of claims 32-49, wherein the antibody is a human antibody.

51.5. An antibody that binds the same epitope as the antibody of claim 3 or claim 4~~any one of claims 10-50~~.

52.6. An antibody that competes with the antibody of claim 3 or claim 4~~any one of claims 10-51~~ for binding to human CD94.

53.7. The antibody of any one of claims 1-61-52, wherein the antibody is an antigen-binding antibody fragment or single chain antibody.

54.8. The antibody of any one of claims 1-61-52, wherein the antibody further comprises an Fc region, optionally a human IgG1 Fc region.

~~55. The antibody of claim 54, wherein the Fc region is a human IgG1 Fc region.~~

~~56.9. The antibody of claim ~~854 or claim 55~~, wherein the antibody:~~

~~(a) comprises a human Fc region that is non-fucosylated;~~

~~(b) binds to a human cellular Fc gamma receptor IIIA to a greater extent than an antibody comprising a wild type human IgG1 Fc region; and/or~~

~~(c) is capable of inducing antibody-dependent cellular cytotoxicity (ADCC) against a cell expressing human CD94 on its surface.~~

~~57. The antibody of any one of claims 54-56, wherein the antibody binds to a human cellular Fc gamma receptor IIIA to a greater extent than an antibody comprising a wild type human IgG1 Fc region.~~

~~58. The antibody of any one of claims 54-57, wherein the antibody is capable of inducing antibody-dependent cellular cytotoxicity (ADCC) against a cell expressing human CD94 on its surface.~~

~~59.10. A polynucleotide encoding the antibody of any one of claims ~~1-91~~58.~~

~~60.11. An expression vector comprising the polynucleotide of claim ~~10~~59.~~

~~61. The vector of claim 60, wherein the vector is an expression vector.~~

~~62.12. An isolated host cell comprising the polynucleotide of claim ~~10~~59 or the vector of claim ~~11~~60 or claim 61.~~

~~63.13. A method of producing an antibody, comprising culturing the host cell of claim ~~12~~62 under conditions suitable for production of the antibody.~~

~~64.14. The method of claim ~~13~~63, wherein the method further ~~comprises~~comprising recovering the antibody from the host cell.~~

~~65.15. A pharmaceutical composition comprising the antibody of any one of claims 1-~~95~~8 and a pharmaceutically acceptable carrier.~~

~~66.16. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicamentA method for treating a disease or disorder in a subject, ~~comprising administering to the subject an effective amount of the antibody of any one of claims 1-58 or the composition of claim 65.~~~~

~~67.17. The use~~method~~ of claim ~~16~~66, wherein administration of the antibody results in a reduction in the number of peripheral blood LGL or NK cells in the subject.~~

~~68.18.~~ The ~~use~~method of claim ~~16-66~~, wherein:

~~(a) the disease or disorder is Felty's syndrome, and wherein administration of the antibody to the subject results in a reduction of one or more Felty's syndrome symptoms in the subject;~~

~~(b) the disease or disorder is inclusion body myositis, and wherein administration of the antibody to the subject results in a reduction of one or more inclusion body myositis symptoms in the subject;~~

~~(c) the disease or disorder is aggressive NK leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more aggressive NK leukemia symptoms in the subject;~~

~~(d) the disease or disorder is rheumatoid arthritis, and wherein administration of the antibody to the subject results in a reduction of one or more rheumatoid arthritis symptoms in the subject;~~

~~(e) the disease or disorder is LGL leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more LGL leukemia symptoms in the subject;~~

~~(f) the disease or disorder is CLPD-NK, and wherein administration of the antibody to the subject results in a reduction of one or more CLPD-NK symptoms in the subject;~~

~~(g) the disease or disorder is natural killer (NK) cell or T-cell lymphoma, and wherein administration of the antibody to the subject results in a reduction of one or more lymphoma symptoms in the subject; or~~

~~(h) the disease or disorder is microscopic colitis, and wherein administration of the antibody to the subject results in a reduction of one or more microscopic colitis symptoms in the subject.~~

~~69. — The method of claim 66, wherein the disease or disorder is inclusion body myositis, and wherein administration of the antibody to the subject results in a reduction of one or more inclusion body myositis symptoms in the subject.~~

~~70. — The method of claim 66, wherein the disease or disorder is aggressive NK leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more aggressive NK leukemia symptoms in the subject.~~

~~71. — The method of claim 66, wherein the disease or disorder is rheumatoid arthritis, and wherein administration of the antibody to the subject results in a reduction of one or more rheumatoid arthritis symptoms in the subject.~~

~~72. — The method of claim 66, wherein the disease or disorder is LGL leukemia, and wherein administration of the antibody to the subject results in a reduction of one or more LGL leukemia symptoms in the subject.~~

~~73. — The method of claim 66, wherein the disease or disorder is CLPD-NK, and wherein administration of the antibody to the subject results in a reduction of one or more CLPD-NK symptoms in the subject.~~

~~74. — The method of claim 66, wherein the disease or disorder is natural killer (NK) cell or T-cell lymphoma, and wherein administration of the antibody to the subject results in a reduction of one or more lymphoma symptoms in the subject.~~

~~75. — The method of claim 66, wherein the disease or disorder is microscopic colitis, and wherein administration of the antibody to the subject results in a reduction of one or more microscopic colitis symptoms in the subject.~~

~~76.19. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament~~A method for reducing the number of peripheral blood LGL and/or NK cells in a subject, comprising administering to the subject an effective amount of the antibody of any one of claims 1-58 or the composition of claim 65.

~~77.20. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament~~A method for inducing ADCC activity in a subject, comprising administering to the subject an effective amount of the antibody of any one of claims 1-58 or the composition of claim 65.

~~78.21. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament~~A method for treating CLPD-NK in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody of any one of claims 1-58 or the composition of claim 65.

~~79. — The method of claim 78, wherein administration of the antibody results in an improvement of one or more CLPD-NK symptoms in the subject.~~

~~80.22. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament for~~A method of treating natural killer (NK) cell or T-cell lymphoma in a subject in need thereof, comprising administering to a subject in need thereof an effective amount of an antibody that binds human CD94.

~~23. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament for treating T-cell lymphoma in a subject in need thereof.~~

~~81. — The method of claim 80, wherein the antibody does not bind to the same epitope on human CD94 as anti-CD94 antibody clones HP-3D9, DX22, 131412, or 12K45.~~

~~82. The method of claim 80, wherein the antibody binds to human CD94 with a greater affinity than anti-CD94 antibody clones HP 3D9, DX22, 131412, and 12K45.~~

~~83.24. The use~~method of ~~claim 22 or claim 23~~any one of claims 74 and 80-82, wherein the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (TCL), enteropathy-associated TCL, cutaneous TCL, anaplastic large cell lymphoma (ALK+), anaplastic large cell lymphoma (ALK-), peripheral TCL, angioimmunoblastic TCL, adult TCL, monomorphic epitheliotropic intestinal TCL, epidermotropic CD8+ cutaneous TCL, primary cutaneous gamma/delta TCL, or subcutaneous panniculitis TCL; optionally wherein the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.

~~84. The method of claim 83, wherein the NK cell or T-cell lymphoma is extranodal NK/T cell lymphoma, hepatosplenic TCL, or enteropathy-associated TCL.~~

~~85.25. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament~~A method for enhancing chimeric antigen receptor T cell (CAR-T) therapy in a human subject in need thereof, ~~wherein~~comprising administering to the subject an effective amount of the ~~medicament~~antibody of any one of claims 1-58 or the composition of claim 65 is to be administered to the subject prior to administration of a CAR-T treatment to the subject.

~~86.26. The use~~method of claim ~~26-85~~, wherein ~~the~~ administration of the antibody or composition results in depletion of NK cells in the subject prior to administration of the CAR-T treatment.

~~87.27. Use of the antibody of any one of claims 1-9 or the composition of claim 15 in the manufacture of a medicament~~A method for depleting CD8+ CD94+ T cells in a human subject in need thereof; ~~comprising administering to the subject an effective amount of the antibody of any one of claims 1-58 or the composition of claim 65.~~

~~88.28. The use~~method of any one of claims ~~16-27~~66-87, ~~wherein~~further comprising administering an IL-2 polypeptide is to be further administered to the subject.

~~89.29. The use~~method of any one of claims ~~16-28~~66-88, wherein the subject is a human.